Jean-François Roux
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jean-François Roux has a total of 145 co-authors. Here are the top co-authors by number of shared publications:
Vidal Essebag
McGill University Health Centre, McGill University, Montreal, Canada
5 shared publications- Jason G. Andrade
Vancouver General Hospital, University of British Columbia, Vancouver, Canada
4 shared publications Bernard Thibault
Department of Medicine, and Research Centre, Montreal Heart Institute, Université de Montréal, Montreal, Canada
3 shared publicationsDenis Roy
Department of Medicine, and Research Centre, Montreal Heart Institute, Université de Montréal, Montreal, Canada
3 shared publicationsFadi Massoud
Centre Hospitalier Charles-LeMoyne, Longueuil, Canada
3 shared publicationsIsabelle Nault
Institut Universitaire de Cardiologie et de Pneumologie de Québec, Université Laval, Quebec City, Canada
3 shared publications
Latest Publications
- Open Access
- 22 October 2026
- Published by Elsevier in American Heart Journal
- Vol. 304, 107632
Design and rationale of a multicenter randomized trial assessing strategies for catheter ablation of persistent atrial fibrillation: The STAR AF 3 trial
- 22 October 2026
- Published by Elsevier in American Heart Journal
- Vol. 304, 107632
Open AccessDesign and rationale of a multicenter randomized trial assessing strategies for catheter ablation of persistent atrial fibrillation: The STAR AF 3 trial
- Open Access
- 4 February 2026
- Published by Springer Nature in Nature Medicine
- Vol. 32 (2) , 767
Publisher Correction: Anticoagulation to prevent ischemic stroke and neurocognitive impairment in atrial fibrillation: the BRAIN-AF randomized clinical trial
- 4 February 2026
- Published by Springer Nature in Nature Medicine
- Vol. 32 (2) , 767
Open AccessPublisher Correction: Anticoagulation to prevent ischemic stroke and neurocognitive impairment in atrial fibrillation: the BRAIN-AF randomized clinical trial
- Top Cited PapersOpen Access
- 7 January 2026
- Published by Springer Nature in Nature Medicine
- Vol. 32 (1) , 297-305
Anticoagulation to prevent ischemic stroke and neurocognitive impairment in atrial fibrillation: the BRAIN-AF randomized clinical trial
Individuals with atrial fibrillation (AF) are at increased risk of stroke, cognitive impairment and dementia. Observational studies suggest that anticoagulation may reduce the risk of cognitive decline in patients with AF and elevated thromboembolic risk, implicating subclinical cerebral emboli as a potential mechanistic link. Whether anticoagulation prevents cognitive deterioration in patients with AF at low risk of stroke remains uncertain. Here we conducted a multicenter, double-blind, placebo-controlled trial in which participants with AF and low thromboembolic risk (CHA2DS2-VASc scores of 0 or 1, excluding female sex) were randomized 1:1 to receive rivaroxaban 15 mg daily or placebo. The primary outcome was a composite of cognitive decline (≥2-point drop in Montreal Cognitive Assessment), stroke or transient ischemic attack with a motor deficit or aphasia. The trial was halted after meeting the predetermined futility criterion following a planned interim analysis, with 1,235 of the intended 1,424 participants (919 men; 316 women) enrolled. Over a median follow-up of 3.7 years, the primary outcome occurred in 256 (20.7%) participants, at an annual rate of 7.0% with rivaroxaban versus 6.4% with placebo, yielding a hazard ratio of 1.10 (95% confidence interval (0.86–1.40); P = 0.46). Conditional power analysis indicated a 1.2% probability of achieving a statistically significant treatment effect if the trial had been continued to its planned total of 410 events. Major bleeding occurred in two patients treated with rivaroxaban (0.09% per year) and five patients treated with placebo (0.21% per year). In conclusion, despite the high incidence of cognitive decline observed among patients with AF and low stroke risk, the BRAIN-AF trial, which tested a low dose of rivaroxaban to prevent stroke, transient ischemic attack and cognitive decline in patients with prior AF, was stopped early due to futility. ClinicalTrials.gov registration: NCT02387229.
- 7 January 2026
- Published by Springer Nature in Nature Medicine
- Vol. 32 (1) , 297-305
Top Cited PapersOpen AccessAnticoagulation to prevent ischemic stroke and neurocognitive impairment in atrial fibrillation: the BRAIN-AF randomized clinical trial
Individuals with atrial fibrillation (AF) are at increased risk of stroke, cognitive impairment and dementia. Observational studies suggest that anticoagulation may reduce the risk of cognitive decline in patients with AF and elevated thromboembolic risk, implicating subclinical cerebral emboli as a potential mechanistic link. Whether anticoagulation prevents cognitive deterioration in patients with AF at low risk of stroke remains uncertain. Here we conducted a multicenter, double-blind, placebo-controlled trial in which participants with AF and low thromboembolic risk (CHA2DS2-VASc scores of 0 or 1, excluding female sex) were randomized 1:1 to receive rivaroxaban 15 mg daily or placebo. The primary outcome was a composite of cognitive decline (≥2-point drop in Montreal Cognitive Assessment), stroke or transient ischemic attack with a motor deficit or aphasia. The trial was halted after meeting the predetermined futility criterion following a planned interim analysis, with 1,235 of the intended 1,424 participants (919 men; 316 women) enrolled. Over a median follow-up of 3.7 years, the primary outcome occurred in 256 (20.7%) participants, at an annual rate of 7.0% with rivaroxaban versus 6.4% with placebo, yielding a hazard ratio of 1.10 (95% confidence interval (0.86–1.40); P = 0.46). Conditional power analysis indicated a 1.2% probability of achieving a statistically significant treatment effect if the trial had been continued to its planned total of 410 events. Major bleeding occurred in two patients treated with rivaroxaban (0.09% per year) and five patients treated with placebo (0.21% per year). In conclusion, despite the high incidence of cognitive decline observed among patients with AF and low stroke risk, the BRAIN-AF trial, which tested a low dose of rivaroxaban to prevent stroke, transient ischemic attack and cognitive decline in patients with prior AF, was stopped early due to futility. ClinicalTrials.gov registration: NCT02387229.
- Open Access
- 1 December 2023
- Published by Wolters Kluwer Health in Circulation: Arrhythmia and Electrophysiology
- Vol. 16 (12) , 639-650
Multicenter, Phase 2, Randomized Controlled Study of the Efficacy and Safety of Etripamil Nasal Spray for the Acute Reduction of Rapid Ventricular Rate in Patients With Symptomatic Atrial Fibrillation (ReVeRA-201)
BACKGROUND: Despite chronic therapies, atrial fibrillation (AF) leads to rapid ventricular rates (RVR) often requiring intravenous treatments. Etripamil is a fast-acting, calcium-channel blocker administered intranasally affecting the atrioventricular node within minutes. METHODS: Reduction of Ventricular Rate in Patients with Atrial Fibrillation evaluated the efficacy and safety of etripamil for the reduction of ventricular rate (VR) in patients presenting urgently with AF-RVR (VR ≥110 beats per minute [bpm]), was randomized, double-blind, placebo-controlled, and conducted in Canada and the Netherlands. Patients presenting urgently with AF-RVR were randomized (1:1, etripamil nasal spray 70 mg: placebo nasal spray). The primary objective was to demonstrate the effectiveness of etripamil in reducing VR in AF-RVR within 60 minutes of treatment. Secondary objectives assessed achievement of VR P <0.0001). VR reductions persisted up to 150 minutes. Significantly greater proportions of patients receiving etripamil achieved VR reductions <100 bpm (with longer median duration <100 bpm), or VR reduction by ≥10% or ≥20%, versus placebo. VR reduction ≥20% occurred in 66.7% of patients in the etripamil arm and no patients in placebo. Using the Treatment Satisfaction Questionnaire for Medication-9, there was significant improvement in satisfaction on symptom relief and treatment effectiveness with etripamil versus placebo. Serious adverse events were rare; 1 patient in the etripamil arm experienced transient severe bradycardia and syncope, assessed as due to hypervagotonia. CONCLUSIONS: Intranasal etripamil 70 mg reduced VR and improved symptom relief and treatment satisfaction. These data support further development of self-administered etripamil for the treatment of AF-RVR. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique Identifier: NCT04467905
- 1 December 2023
- Published by Wolters Kluwer Health in Circulation: Arrhythmia and Electrophysiology
- Vol. 16 (12) , 639-650
Open AccessMulticenter, Phase 2, Randomized Controlled Study of the Efficacy and Safety of Etripamil Nasal Spray for the Acute Reduction of Rapid Ventricular Rate in Patients With Symptomatic Atrial Fibrillation (ReVeRA-201)
BACKGROUND: Despite chronic therapies, atrial fibrillation (AF) leads to rapid ventricular rates (RVR) often requiring intravenous treatments. Etripamil is a fast-acting, calcium-channel blocker administered intranasally affecting the atrioventricular node within minutes. METHODS: Reduction of Ventricular Rate in Patients with Atrial Fibrillation evaluated the efficacy and safety of etripamil for the reduction of ventricular rate (VR) in patients presenting urgently with AF-RVR (VR ≥110 beats per minute [bpm]), was randomized, double-blind, placebo-controlled, and conducted in Canada and the Netherlands. Patients presenting urgently with AF-RVR were randomized (1:1, etripamil nasal spray 70 mg: placebo nasal spray). The primary objective was to demonstrate the effectiveness of etripamil in reducing VR in AF-RVR within 60 minutes of treatment. Secondary objectives assessed achievement of VR P <0.0001). VR reductions persisted up to 150 minutes. Significantly greater proportions of patients receiving etripamil achieved VR reductions <100 bpm (with longer median duration <100 bpm), or VR reduction by ≥10% or ≥20%, versus placebo. VR reduction ≥20% occurred in 66.7% of patients in the etripamil arm and no patients in placebo. Using the Treatment Satisfaction Questionnaire for Medication-9, there was significant improvement in satisfaction on symptom relief and treatment effectiveness with etripamil versus placebo. Serious adverse events were rare; 1 patient in the etripamil arm experienced transient severe bradycardia and syncope, assessed as due to hypervagotonia. CONCLUSIONS: Intranasal etripamil 70 mg reduced VR and improved symptom relief and treatment satisfaction. These data support further development of self-administered etripamil for the treatment of AF-RVR. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique Identifier: NCT04467905
- 1 August 2019
- Published by Elsevier in Canadian Journal of Cardiology
- Vol. 35 (8) , 1069-1077
Blinded Randomized Trial of Anticoagulation to Prevent Ischemic Stroke and Neurocognitive Impairment in Atrial Fibrillation (BRAIN-AF): Methods and Design
- 1 August 2019
- Published by Elsevier in Canadian Journal of Cardiology
- Vol. 35 (8) , 1069-1077
Blinded Randomized Trial of Anticoagulation to Prevent Ischemic Stroke and Neurocognitive Impairment in Atrial Fibrillation (BRAIN-AF): Methods and Design
- Open Access
- 1 November 2016
- Published by Elsevier in Indian Pacing and Electrophysiology Journal
- Vol. 16 (6) , 181-184
Real-life experience with a new anticoagulation regimen for patients undergoing left-sided ablation procedures
- 1 November 2016
- Published by Elsevier in Indian Pacing and Electrophysiology Journal
- Vol. 16 (6) , 181-184
Open AccessReal-life experience with a new anticoagulation regimen for patients undergoing left-sided ablation procedures
- Open Access
- 2 August 2016
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 19 (1) , 21-28
Intracardiac echo-facilitated 3D electroanatomical mapping of ventricular arrhythmias from the papillary muscles: assessing the ‘fourth dimension’ during ablation
Ventricular arrhythmias (VA) originating from a papillary muscle (PM) have recently been described as a distinct clinical entity with peculiar features that make its treatment with catheter ablation challenging. Here, we report our experience using an intracardiac echo-facilitated 3D electroanatomical mapping approach in a case series of patients undergoing ablation for PM VA. Sixteen patients who underwent catheter ablation for ventricular tachycardia (VT) or symptomatic premature ventricular contractions originating from left ventricular PMs were included in the study. A total of 24 procedures (mean 1.5 per patient) were performed: 15 using a retrograde aortic approach and 9 using a transseptal approach. Integrated intracardiac ultrasound for 3D electroanatomical mapping was used in 15 of the 24 procedures. The posteromedial PM was the most frequent culprit for the clinical arrhythmia, and the body was the part of the PM most likely to be the successful site for ablation. The site of ablation was identified based on the best pace map matching the clinical arrhythmia and the site of earliest the activation. At a mean follow-up of 10.5 ± 7 months, only two patients had recurrent arrhythmias following a repeat ablation procedure. An echo-facilitated 3D electroanatomical mapping allows for real-time creation of precise geometries of cardiac chambers and endocavitary structures. This is useful during procedures such as catheter ablation of VAs originating from PMs, which require detailed representation of anatomical landmarks. Routine adoption of this technique should be considered to improve outcomes of PM VA ablation.
- 2 August 2016
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 19 (1) , 21-28
Open AccessIntracardiac echo-facilitated 3D electroanatomical mapping of ventricular arrhythmias from the papillary muscles: assessing the ‘fourth dimension’ during ablation
Ventricular arrhythmias (VA) originating from a papillary muscle (PM) have recently been described as a distinct clinical entity with peculiar features that make its treatment with catheter ablation challenging. Here, we report our experience using an intracardiac echo-facilitated 3D electroanatomical mapping approach in a case series of patients undergoing ablation for PM VA. Sixteen patients who underwent catheter ablation for ventricular tachycardia (VT) or symptomatic premature ventricular contractions originating from left ventricular PMs were included in the study. A total of 24 procedures (mean 1.5 per patient) were performed: 15 using a retrograde aortic approach and 9 using a transseptal approach. Integrated intracardiac ultrasound for 3D electroanatomical mapping was used in 15 of the 24 procedures. The posteromedial PM was the most frequent culprit for the clinical arrhythmia, and the body was the part of the PM most likely to be the successful site for ablation. The site of ablation was identified based on the best pace map matching the clinical arrhythmia and the site of earliest the activation. At a mean follow-up of 10.5 ± 7 months, only two patients had recurrent arrhythmias following a repeat ablation procedure. An echo-facilitated 3D electroanatomical mapping allows for real-time creation of precise geometries of cardiac chambers and endocavitary structures. This is useful during procedures such as catheter ablation of VAs originating from PMs, which require detailed representation of anatomical landmarks. Routine adoption of this technique should be considered to improve outcomes of PM VA ablation.